These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36413930)

  • 1. Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement.
    Wei X; Yu G; Shen H; Luo Y; Shang T; Shen R; Xi M; Sun H
    Bioorg Chem; 2023 Jan; 130():106278. PubMed ID: 36413930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDE4 as a target for cognition enhancement.
    Richter W; Menniti FS; Zhang HT; Conti M
    Expert Opin Ther Targets; 2013 Sep; 17(9):1011-27. PubMed ID: 23883342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implication of Phosphodiesterase-4-Inhibition.
    Schick MA; Schlegel N
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 4 inhibitors in diabetic nephropathy.
    Ookawara M; Nio Y
    Cell Signal; 2022 Feb; 90():110185. PubMed ID: 34785349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the development of phosphodiesterase-4 inhibitors.
    Li G; He D; Cai X; Guan W; Zhang Y; Wu JQ; Yao H
    Eur J Med Chem; 2023 Mar; 250():115195. PubMed ID: 36809706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D.
    Sierksma AS; van den Hove DL; Pfau F; Philippens M; Bruno O; Fedele E; Ricciarelli R; Steinbusch HW; Vanmierlo T; Prickaerts J
    Neuropharmacology; 2014 Feb; 77():120-30. PubMed ID: 24067928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the Development of Phosphodiesterase-4 Inhibitors.
    Peng T; Qi B; He J; Ke H; Shi J
    J Med Chem; 2020 Oct; 63(19):10594-10617. PubMed ID: 32255344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
    Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
    Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.
    Wu C; Rajagopalan S
    Obes Rev; 2016 May; 17(5):429-41. PubMed ID: 26997580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting phosphodiesterase 4 as a potential therapy for Parkinson's disease: a review.
    Nongthombam PD; Haobam R
    Mol Biol Rep; 2024 Apr; 51(1):510. PubMed ID: 38622307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Past, Present, and Future of Phosphodiesterase-4 Modulation for Age-Induced Memory Loss.
    Hansen RT; Zhang HT
    Adv Neurobiol; 2017; 17():169-199. PubMed ID: 28956333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential.
    Roy D; Balasubramanian S; Krishnamurthy PT; Sola P; Rymbai E
    Cell Mol Neurobiol; 2023 Aug; 43(6):2713-2741. PubMed ID: 37074485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase Type 4 Inhibition in CNS Diseases.
    Blokland A; Heckman P; Vanmierlo T; Schreiber R; Paes D; Prickaerts J
    Trends Pharmacol Sci; 2019 Dec; 40(12):971-985. PubMed ID: 31704172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase-4 modulation as a potential therapeutic for cognitive loss in pathological and non-pathological aging: possibilities and pitfalls.
    Hansen RT; Zhang HT
    Curr Pharm Des; 2015; 21(3):291-302. PubMed ID: 25159075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors.
    Paes D; Schepers M; Rombaut B; van den Hove D; Vanmierlo T; Prickaerts J
    Pharmacol Rev; 2021 Jul; 73(3):1016-1049. PubMed ID: 34233947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDE4 inhibitors for disease therapy: advances and future perspective.
    Du B; Luo M; Ren C; Zhang J
    Future Med Chem; 2023 Jul; 15(13):1185-1207. PubMed ID: 37470147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
    Page CP; Spina D
    Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase-4D Knock-down in the Prefrontal Cortex Alleviates Chronic Unpredictable Stress-Induced Depressive-Like Behaviors and Memory Deficits in Mice.
    Wang ZZ; Yang WX; Zhang Y; Zhao N; Zhang YZ; Liu YQ; Xu Y; Wilson SP; O'Donnell JM; Zhang HT; Li YF
    Sci Rep; 2015 Jul; 5():11332. PubMed ID: 26161529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling.
    Li YF; Cheng YF; Huang Y; Conti M; Wilson SP; O'Donnell JM; Zhang HT
    J Neurosci; 2011 Jan; 31(1):172-83. PubMed ID: 21209202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase β2-Agonist-Induced Expression of Antiinflammatory Mitogen-Activated Protein Kinase Phosphatase 1 in Airway Smooth Muscle Cells.
    Patel BS; Prabhala P; Oliver BG; Ammit AJ
    Am J Respir Cell Mol Biol; 2015 May; 52(5):634-40. PubMed ID: 25296132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.